Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Xenon Pharmaceuticals Inc shares valued at $903,214 were sold by MORTIMER IAN on Jan 24 ’25. At $40.20 per share, MORTIMER IAN sold 22,468 shares. The insider’s holdings dropped to 31,302 shares worth approximately $0.91 million following the completion of this transaction.
Also, MORTIMER IAN sold 16,315 shares, netting a total of over 660,806 in proceeds. Following the sale of shares at $40.50 each, the insider now holds 31,302 shares.
Before that, MORTIMER IAN had sold 16,217 shares from its account. In a trade valued at $649,977, the PRESIDENT & CEO traded Xenon Pharmaceuticals Inc shares for $40.08 each. Upon closing the transaction, the insider’s holdings decreased to 16,217 shares, worth approximately $0.91 million.
As published in their initiating research note from Chardan Capital Markets on May 07, 2025, Xenon Pharmaceuticals Inc [XENE] has been a Buy and the price target has been revised to $55. Analysts at Deutsche Bank started covering the stock with ‘”a Buy”‘ outlook in a report released in mid February. Earlier on October 01, 2024, H.C. Wainwright initiated its rating. Their recommendation was “a Buy” for XENE stock.
Analyzing XENE Stock Performance
During the last five days, there has been a drop of approximately -4.66%. Over the course of the year, Xenon Pharmaceuticals Inc shares have dropped approximately -25.92%. Shares of the company reached a 52-week high of $42.23 on 01/02/25 and a 52-week low of $26.74 on 04/09/25.
Support And Resistance Levels for Xenon Pharmaceuticals Inc (XENE)
According to the 24-hour chart, there is a support level at 28.38, which, if violated, would cause prices to drop to 27.72. In the upper region, resistance lies at 29.64. The next price resistance is at 30.24. RSI (Relative Strength Index) is 34.92 on the 14-day chart, showing neutral technical sentiment.
